73 related articles for article (PubMed ID: 38514186)
1. Prevention and treatment of HPV-related cancer through a mRNA vaccine expressing APC-targeting antigen.
Li X; Wang H; Lai W; Liao J; Mo W; Huang K; He L; Liang X; Yu Z; Xu J; Hua X; Hou F; Ding J; Jia WW; Zhang K; Wang Y
Immunology; 2024 Jul; 172(3):375-391. PubMed ID: 38471664
[TBL] [Abstract][Full Text] [Related]
2. Development of novel HPV therapeutic vaccine constructs based on engineered exosomes and tumor cell lysates.
Rezaei F; Bolhassani A; Sadat SM; Arashkia A; Fotouhi F; Milani A; Pordanjani PM
Life Sci; 2024 Mar; 340():122456. PubMed ID: 38266814
[TBL] [Abstract][Full Text] [Related]
3. A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity.
Zhao X; Zhang Y; Trejo-Cerro O; Kaplan E; Li Z; Albertsboer F; El Hammiri N; Mariz FC; Banks L; Ottonello S; Müller M
NPJ Vaccines; 2024 Jun; 9(1):119. PubMed ID: 38926425
[TBL] [Abstract][Full Text] [Related]
4. Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
Weaver AN; Iams WT; Park JC; Mita M; Holtick U; Gordon MS; Rodabaugh KJ; Dhani N; Neupane P; Taylor M; Amanda Duvall E; Jennings J; Miselis NR; Loughhead S; Warren MS; Bernstein H; Klussmann JP; Baranda J; Jimeno A
Mol Carcinog; 2024 May; ():. PubMed ID: 38695604
[TBL] [Abstract][Full Text] [Related]
5. T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.
Fert I; Douguet L; Vesin B; Moncoq F; Noirat A; Authié P; Ciret S; Le Chevalier F; Blanc C; Vitrenko Y; Charneau P; Majlessi L; Anna F
NPJ Vaccines; 2024 Jun; 9(1):102. PubMed ID: 38858404
[TBL] [Abstract][Full Text] [Related]
6. TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers.
Barrios K; Celis E
Cancer Immunol Immunother; 2012 Aug; 61(8):1307-17. PubMed ID: 22527249
[TBL] [Abstract][Full Text] [Related]
7. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
Front Immunol; 2020; 11():188. PubMed ID: 32133000
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies.
Wang J; Ma L; Chen Y; Zhou R; Wang Q; Zhang T; Yi D; Liu Q; Zhang Y; Zhang W; Dong Y; Cen S
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38514186
[TBL] [Abstract][Full Text] [Related]
9. Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies.
Wang J; Wang Q; Ma L; Lv K; Han L; Chen Y; Zhou R; Zhou H; Chen H; Wang Y; Zhang T; Yi D; Liu Q; Zhang Y; Li X; Cheng T; Zhang J; Huang C; Dong Y; Zhang W; Cen S
Mol Ther; 2024 May; ():. PubMed ID: 38715363
[TBL] [Abstract][Full Text] [Related]
10. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
11. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
12. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
13. mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization.
Lee S; Yoon H; Hong SH; Kwon SP; Hong JJ; Kwak HW; Park HJ; Yoo S; Bae SH; Park HJ; Lee J; Bang YJ; Lee YS; Kim JY; Yoon S; Roh G; Cho Y; Kim Y; Kim D; Park SI; Kim DH; Lee S; Oh A; Ha D; Lee SY; Park M; Hwang EH; Bae G; Jeon E; Park SH; Choi WS; Oh HR; Kim IW; Youn H; Keum G; Bang EK; Rhee JH; Lee SE; Nam JH
J Med Virol; 2023 Dec; 95(12):e29309. PubMed ID: 38100632
[TBL] [Abstract][Full Text] [Related]
14. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability.
Zhang L; More KR; Ojha A; Jackson CB; Quinlan BD; Li H; He W; Farzan M; Pardi N; Choe H
NPJ Vaccines; 2023 Oct; 8(1):156. PubMed ID: 37821446
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
